Cost effectiveness of treatments for wet age-related macular degeneration

PharmacoEconomics

Volumn 29, Issue 2, 2011, Pages 107-131

  Mitchell, Paul ^a   Annemans, Lieven ^b   White, Richard ^c   Gallagher, Meghan ^d   Thomas, Simu ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GHENT UNIVERSITY   (Belgium)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VERTEPORFIN; VITAMIN;

AUSTRALIA; BREAST CANCER; CANADA; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEALTH; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; LASER COAGULATION; LUNG NON SMALL CELL CANCER; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; SYSTEMATIC REVIEW; UNITED KINGDOM; VISUAL ACUITY;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; MACULAR DEGENERATION; WET MACULAR DEGENERATION;

EID: 78751636930     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11585520-000000000-00000     Document Type: Review

References (74)

1. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading systemfor age-relatedmaculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-74
2. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008 May; 12 (16): iii-iv, ix-201
3. Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology 1987; 94: 1191-5
4. Lafuma A, Brezin A, Fagnani F, et al. Nonmedical economic consequences attributable to visual impairment: a nationwide approach in France. Eur JHealth Econ 2006; 7: 158-64
5. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006; 90: 272-5
6. Lafuma A, Brezin A, Lopatriello S, et al. Evaluation of nonmedical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics 2006; 24 (2): 193-205
7. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44
9. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
10. Brown GC, Brown MM, Sharma S, et al. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000; 107: 1374-80
11. Brown GC, Brown MM, Brown HC, et al. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007; 114: 1170-8
12. Busbee BG, Brown MM, Brown GC, et al. CME review: a cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003; 23: 279-87
13. Larouche K, Rochon S. Evaluation of photodynamic therapy for the treatment of exudative age-related macular degeneration (ARMD) with subfoveal neovascularization. Montreal (QC): Agence dévaluation des technologies et des modes dintervention en santé, 2005 [online]. Available from URL: http://www.aetmis.gouv.qc.ca/site/download. php?f= 98a72111492a641cb55a200773a47eba [Accessed 2010 Apr 26]
14. Bansback N, Davis S, Brazier J. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye 2007; 21: 1455-63
15. Brown GC, Brown MM, Campanella J, et al. The costutility of photodynamic therapy in eyes with neovascular macular degeneration: a value-based reappraisal with 5-year data. Am J Ophthalmol 2005; 140: 679-87
16. Donati G. Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in agerelated macular degeneration in routine clinical practice in Switzerland. J Fr Ophtalmol 2007; 30: 837-41
17. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age-related macular degeneration. Br J Ophthalmol 2004; 88: 982-7
18. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2003; 7 (9): v-vi, 1-98
19. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to agerelated macular degeneration. Ophthalmology 2001; 108: 2051-9 (Pubitemid 33032778)
20. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004; 88: 1107-12
21. Earnshaw SR, Moride Y, Rochon S. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clin Ther 2007; 29: 2096-106
22. Javitt JC, Zlateva GP, Earnshaw SR, et al. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value Health 2008; 11: 563-74
23. Wolowacz SE, Roskell N, Kelly S, et al. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in theUK. Pharmacoeconomics 2007; 25 (10): 863-79
24. Brown MM, Brown GC, Brown HC, et al. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115: 1039-45
25. Canadian Agency for Drugs and Technologies in Health. Common drug review: ranibizumab (Lucentis-Novartis Pharmaceuticals Canada Inc.). Indication: age-related macular degeneration (AMD). Overview of CDR clinical and pharmacoeconomic reports August 2008. Ottawa (ON): CADTH, 2008 [online]. Available from URL: http://www.cadth.ca/media/cdr/relatedinfo/cdr-trans- Lucentis-overview-Jul-30-08-e.pdf [Accessed 2010 May 7]
26. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008 Jun 24; 6: 12
27. Neubauer AS, Holz FG, Schrader W, et al. Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration. Klin Monbl Augenheilkd 2007; 224: 727-32
28. Brown A, Hodge W, Kymes S, et al. Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2008
29. Fletcher EC, Lade RJ, Adewoyin T, et al. Computerized model of cost-utility analysis for treatment of age-related macular degeneration. Ophthalmology 2008; 115: 2192-8
30. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther 2008; 30: 2436-51
31. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009; 248: 467-76
32. Smiddy WE. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology 2007; 114: 847-54
33. No authors listed. Photodynamic therapy of subfoveal choroidal neovascularization in age-relatedmacular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Study Group [published erratum appears in Arch Ophthalmol 2000; 118 (4): 488]. Arch Ophthalmol 1999; 117 (10): 1329-45
34. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001; 16: 218-22
35. Australian Government, Department of Health and Ageing. Medical Services Advisory Committee (MSAC). Photodynamic therapy with verteporfin for macular degeneration. Canberra (ACT): MSAC, 2001
36. Muslera E, Natal C. Cost-effectiveness of photodynamic therapy in age-related macular degeneration. Arch Soc Esp Oftalmol 2006; 81: 199-204
37. Cohen SY, Bremond-Gignac D, Quentel G, et al. Costeffectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1527-34
38. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009; 116: 481-7
39. Augustovski F, Colantonio L, Pichon Riviere A. Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment. Buenos Aires: Institute for Clinical Effectiveness and Health Policy, 2007
40. Australian Government, Department of Health and Ageing. Pharmaceutical Benefits Advisory Committee. Public summary document: ranibizumab. Canberra (ACT): Pharmaceutical Benefits Advisory Committee, 2007 [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/ 8273CE4F07D2021FCA2572F800047B3B/File/Ranibizumab.pdf [Accessed 2010 Apr 27]
41. Scottish Medicines Consortium. Ranibizumab 10 mg/ml solution for intravitreal injection (Lucentis-). Glasgow: Scottish Medicines Consortium, 2007
42. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-48
43. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variabledosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58
44. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83
45. Steinbrook R. The price of sight: ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355: 1409-12
46. Yang YC. Developments in treatment of AMD: therapeutic intervention - anti VEGF therapy [online]. Available from URL: http://evslarchive.moorfields. nhs.uk/amd-docs-0607/Anti%20VEGF%20Tx%20.pdf [Accessed 2010 Jun 10]
47. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007; 91: 1244-6
48. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 2010 Jun 9; 340: c2459
49. Andriolo RB, Puga ME, Belfort Jr R, et al. Bevacizumab for ocular neovascular diseases: a systematic review. Sao Paulo Med J 2009; 127: 84-91
50. National Eye Institute (NEI). Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial [ClinicalTrials.gov identifier NCT00593450].USNational Institutes ofHealth, ClinicalTrials.gov [online].Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Nov 26]
51. The Bandolier Group. Lucentis versus avastin: needs must or devil drives? [online]. Available from URL: http:// www.medicine.ox.ac.uk/bandolier/band159/ b159-5.html [Accessed 2009 Oct 13]
52. Kahook MY, Liu L, Ruzycki P, et al. High-molecularweight aggregates in repackaged bevacizumab. Retina 2010; 30: 887-92
53. Olsen TW. Treatment of exudative age-related macular degeneration: many factors to consider. Am J Ophthalmol 2007; 144: 281-3
54. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114: 2179-82
55. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-9
56. Boyer DS, Heier JS, Brown DM, et al. A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731-9
57. Agence francaise de securite sanitaire des produits de sante (AFSSAPS). Utilisation hors AMM dAvastin-Point dinformation [online] Available from URL: http://www.afssaps.fr/Infos-de-securite/Points-d-information-Points-detape/ Utilisation-hors-AMM-d-Avastin-R-Point-d-information/(language)/fre-FR [Accessed 2009 Oct 20]
58. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-9
59. Williams GA. What are the legal issues regarding the use of off-label drugs? Retina Today 2007 Jan/Feb: 43-7
60. MHRA and CHM. Hot topics: off-label use of unlicensed medicines. Prescribers responsibilities. Drug Safety Update 2009; 2: 6-7
61. Hopley C, Salkeld G, Wang JJ, et al. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants. Br J Ophthalmol 2004; 88: 450-4 (Pubitemid 38437856)
62. Rein DB, Saaddine JB, Wittenborn JS, et al. Technical appendix: cost-effectiveness of vitamin therapy for agerelated macular degeneration. Ophthalmology 2007; 114: e13-20
63. Rein DB, Saaddine JB, Wittenborn JS, et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration. Ophthalmology 2007; 114: 1319-26
64. Swedish Council on Technology Assessment in Health Care. Photodynamic treatment for macular degeneration. Stockholm: Swedish Council on Technology Assessment in Health Care, 2001
65. Scottish Medicines Consortium. Pegaptanib 0.3 mg, solution for intravitreal injection (Macugen-). Glasgow: Scottish Medicines Consortium, 2006
66. Australian Government, Department of Health and Ageing. Public summary document: verteporfin. Canberra (ACT): Pharmaceutical Benefits Advisory Committee, 2005
67. Oliva G. Photodynamic therapy in the treatment of age-related macular degeneration (update). Barcelona: Catalan Agency for Health Technology Assessment and Research, 2006
68. National Agency for Accreditation and Evaluation in Health (ANAES). Treatment of age-related macular degeneration. Paris: ANAES, 2001
69. Meads C, MooreD. The clinical effectiveness and cost utility of photodynamic therapy for age-related macular degeneration: REP Committee draft report with amendments. Birmingham: Regional Evaluation Panel (REP), 2001 [online]. Available from URL: http://www.rep.bham.ac.uk/2001/Age-related- Macular-Degeneration.pdf [Accessed 2010 Nov 26]
70. Attebo K,Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study. Ophthalmology 1996; 103: 357-64
71. OShea JG. Age-related macular degeneration: a leading cause of blindness. Med J Aust 1996; 165: 561-4
72. Owsley C, Sloane ME. Contrast sensitivity, acuity, and the perception of real-world targets. Br J Ophthalmol 1987; 71: 791-6
73. Bandello F, Augustin A, Sahel JA, et al. Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy. Drugs Aging 2008; 25: 255-68
74. Royal Group of Hospitals Trust (UK). A randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation [ISRCTN92166560]. ISRCTN Register [online]. Available from URL: http:// controlled-trials.com/ISRCTN92166560/ISRCTN92166560 [Accessed 2010 May 1]